Abstract: In accordance with the invention, a compound with a protective action for nerve cell can be reselected by adding PPAR? agonist to a culture cell system where toxic substances such as thapsigargin, MPP+ and staurosporine are preliminarily allowed to react and reselecting a compound improving the survival rate. The compound selected by such method can be used as an active ingredient of a therapeutic agent for neurodegenerative diseases such as cerebral infarction and Parkinson's disease. Thus, the invention is very useful for research works for creating novel pharmaceutical agent.

Abstract: The invention is to provide an antidementic and/or antiamnesic potency enhancer that comprises an aminopiperazine or aminopiperidine derivative of a formula: (wherein R1 is a lower alkyl, etc.; R2 is hydrogen, etc.; R3 is an aryl, etc.; A is —CO—, etc.; X is N or CH; Y is —CO—, etc.), for attaining higher antidementic and/or antiamnesic potency.

Abstract: The present invention provides a method of specifically potentiating an N-type Ca2+ channel activity, which includes administering, to a subject, a compound of the following formula (I): wherein R1 is lower alkyl, aryl, ar(lower)alkoxy or a heterocyclic group, the above groups being optionally substituted by halogen, R2 is hydrogen atom or lower alkyl, R3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO2— or lower alkylene, and Y shows —CO—, —SO2— or —CONH— (compound (I)), a salt thereof, a prodrug thereof or a solvate thereof; a method for the prophylaxis or treatment of brain disorders such as dementia and amnesia, which includes such administration; and a screening method particularly useful for screening a compound having a similar effect as compound (I).

Abstract: Preventives and/or remedies for Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder which contain as the active ingredient an adenosine A1A2a receptor dual antagonist or salts thereof.

Abstract: Tacrolimus derivatives having high levels of neurotrophic activity and low levels of immunosuppressive activity. These compounds are useful as neurotrophic agents, particularly, for preventing or treating neuronal injury/dysfunction.

Abstract: A quinazolinone derivatives having poly (adenosine 5′-diphaspho-ribose)polymerase (PARP) inhibotory activity represented by the formula (I), wherein R1 is optionally substituted cyclic amino groups or optionally substituted amino group, R2 is substituent, n means an integer from 0 to 4, and L is lower akkylene or lower alkenylene, or its prodrug, or their salts.

Abstract: The invention is to provide an antidementic and/or antiamnesic potency enhancer that comprises an aminopiperazine or aminopiperidine derivative of a formula: 1

Abstract: The present invention relates to an agent for the expression of long-term potentiation of synaptic transmission, which contains a compound having a brain somatostatin activation property as an active ingredient and to a screening method of an agent for the expression of long-term potentiation of synaptic transmission, which uses a somatostatin releasing property as an index. The present invention is useful for the prophylaxis and/or treatment of cerebral diseases of dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease, psychosomatic disease and the like.

Abstract: The present invention provides a method of specifically potentiating an N-type Ca2+ channel activity, which includes administering, to a subject, a compound of the following formula (I): 1

Abstract: The present invention relates to an agent for the expression of long-term potentiation of synaptic transmission, which contains a compound having a brain somatostatin activation property as an active ingredient and to a screening method of an agent for the expression of long-term potentiation of synaptic transmission, which uses a somatostatin releasing property as an index The present invention is useful for the prophylaxis and/or treatment of cerebral diseases of dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease, psychosomatic disease and the like.

Abstract: The present invention relates to an agent for the expression of long-term potentiation of synaptic transmission, which contains a compound having a brain somatostatin activation property as an active ingredient and to a screening method of an agent for the expression of long-term potentiation of synaptic transmission, which uses a soniatostatin releasing property as an index. The present invention is useful for the prophylaxis and/or treatment of cerebral diseases of dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease, psychosomatic disease and the like.